Nuclear Medicine: Page 105

Lantheus posts flat Q3 results despite US contrast growth

By AuntMinnie.com staff writers

Strong U.S. sales of its Definity ultrasound contrast agent and stable revenues from U.S. nuclear products helped Lantheus Holdings offset international doldrums in the company's third-quarter financial report.

November 1, 2016

DMS again drives Digirad results higher

By AuntMinnie.com staff writers

Nuclear medicine firm Digirad saw sharp growth in revenue for its third quarter thanks to the addition of sales from its acquisition of DMS Health in January 2016. The company posted a net loss for the period, however.

October 31, 2016

Jubilant Pharma taps new DraxImage president

By AuntMinnie.com staff writers

Jubilant Pharma, parent company of radiopharmaceutical developer Jubilant DraxImage, has appointed a new president to the subsidiary, Michael Rossi. His post is effective immediately.

October 26, 2016

Second Opinion: Did thyroid imaging study miss the mark?

By Dr. Mark Tulchinsky

In an article published July 21 in BMJ, researchers from the University of Michigan Comprehensive Cancer Center questioned whether the use of imaging after treatment for thyroid cancer improved patient outcomes. Dr. Mark Tulchinsky of Pennsylvania State University offers a response in this Second Opinion column.

October 26, 2016

Nuclear med, radiopharmaceutical market primed for growth

By AuntMinnie.com staff writers

The global market for nuclear medicine equipment and radiopharmaceuticals generated $4.7 billion in revenues in 2016 and is expected to grow at a compound annual growth rate of 9.3% to reach $7.3 billion by 2021, according to a new report from MarketsandMarkets.

October 24, 2016

Blue Earth PET radiotracer IDs prostate cancer recurrence

By AuntMinnie.com staff writers

Radiopharmaceutical developer Blue Earth Diagnostics is highlighting results from a phase III clinical trial of its Axumin (fluciclovine F-18) PET radiopharmaceutical agent indicating a 68% detection rate for prostate cancer recurrence.

October 23, 2016

CMR Naviscan highlights PEM study

By AuntMinnie.com staff writers

PET developer Compañía Mexicana de Radiología (CMR) Naviscan is highlighting clinical results regarding positron emission mammography (PEM) published September 2 in European Radiology.

October 20, 2016

Scientist recognized for molybdenum-99 work

By AuntMinnie.com staff writers

A scientist at Los Alamos National Laboratory has been recognized by the U.S. National Nuclear Security Administration for his work in medical isotope production.

October 20, 2016

Philips collaborates with FluoroPharma for CardioPET study

By AuntMinnie.com staff writers

Philips Healthcare said it has collaborated with radiopharmaceutical developer FluoroPharma Medical on a phase II clinical trial for FluoroPharma's CardioPET radiopharmaceutical.

October 18, 2016

Kromek announces new contracts worth $3M

By AuntMinnie.com staff writers

Radiation detection technology firm Kromek has received new contracts worth more than $3 million, including agreements with the U.S. Defense Threat Reduction Agency and the U.K. Ministry of Defense.

October 16, 2016

Perma-Fix to get $10M investment

By AuntMinnie.com staff writers

Perma-Fix Environmental Services has signed a letter of intent with a private investor to sell $10 million of preferred shares in its wholly owned subsidiary, Perma-Fix Medical.

October 13, 2016

Novel hybrid modality could reshape imaging

By AuntMinnie.com staff writers

Two physicists at the University of Virginia have combined MR and gamma-ray imaging to potentially create a new way of producing high-resolution medical images, according to a study published in Nature.

October 12, 2016

Previous Page

Page 105 of 440

Next Page